Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) granted non-statutory stock options to purchase 566,890 shares of common stock to new employees as an employment inducement. The options, issued at an exercise price of $2.24 per share, equal the closing stock price on the grant date of November 16, 2022. Notably, 470,000 shares vest over four years, while 96,890 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at fostering talent for ongoing clinical trials evaluating its telomerase inhibitor, imetelstat.
Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will participate in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:55 a.m. ET in New York City. The session will be accessible via a webcast on Geron's Investor Relations website, with an archive available for 30 days post-event. Geron is focused on developing treatments for hematologic malignancies, with ongoing Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and relapsed/refractory myelofibrosis.
Geron Corporation (NASDAQ: GERN) announced promising data from its IMerge Phase 2 study on Imetelstat, a telomerase inhibitor, showing over 29% of lower risk MDS patients achieved greater than one-year transfusion independence. The upcoming ASH Annual Meeting will feature multiple abstracts highlighting its efficacy in hematologic malignancies, with Phase 3 IMerge trial top-line results expected in early January 2023. Imetelstat's safety profile is consistent, with reversible adverse effects. The research indicates potential disease-modifying activity, addressing significant needs in blood cancer treatments.
Geron Corporation (Nasdaq: GERN) reported its Q3 2022 financial results, revealing a net loss of $41.1 million ($0.10 per share), up from $26.7 million ($0.08 per share) in Q3 2021. Revenues were $297,000, a significant increase from $109,000 in the same period last year. The company has approximately $195 million in cash, with additional resources expected to fund operations through mid-2024. Top-line results from the IMerge Phase 3 trial on imetelstat are anticipated in January 2023, with a New Drug Application submission planned for 2023. Geron projects total operating expenses for 2022 between $155 million and $165 million.
Geron Corporation (NASDAQ: GERN) will announce its Q3 2022 financial results before the market opens on November 3, 2022. A conference call will be held at 9:00 a.m. ET the same day to discuss these results and key milestones. Participants can access the call via a live webcast or by phone. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently undergoing two Phase 3 clinical trials for hematologic malignancies.
On October 19, 2022, Geron Corporation (NASDAQ: GERN) granted non-statutory stock options for 843,260 shares of common stock to newly hired employees. The options have an exercise price of $2.25, matching the closing price on the grant date. Of these, 710,000 shares will vest over four years, while 133,260 shares will vest upon achieving regulatory milestones. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and supports Geron's commitment to developing its telomerase inhibitor, imetelstat, currently in two Phase 3 trials for hematologic malignancies.
Geron Corporation (NASDAQ: GERN) announced the granting of stock options to purchase 901,950 shares of common stock to newly hired employees as an inducement for employment. The options were issued on September 21, 2022, at an exercise price of $2.54 per share, equal to the stock's closing price on that day. Of the total, 495,800 shares vest over four years while 406,150 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq rules and Geron's 2018 Inducement Award Plan.
Geron Corporation (NASDAQ: GERN) appointed John F. McDonald to its Board of Directors effective September 7, 2022. McDonald, a seasoned executive with over 30 years in the biopharmaceutical industry, aims to enhance Geron's strategic and commercial objectives, particularly in advancing imetelstat. His past roles include leadership positions at Novo Nordisk and Biogen. The company's clinical focus remains on the telomerase inhibitor, imetelstat, currently undergoing two Phase 3 trials for hematologic malignancies, with top-line results expected in early January 2023.
Geron Corporation (Nasdaq: GERN) has announced that CEO John A. Scarlett will present at three major investor conferences in New York City. The events include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Baird 2022 Global Healthcare Conference on September 14, 2022. Webcasts will be available on Geron's website and archived for 30 days. Geron focuses on developing its first-in-class telomerase inhibitor, imetelstat, for treating hematologic malignancies.
Geron Corporation (NASDAQ: GERN) has initiated the IMproveMF Phase 1 study, aimed at evaluating the combination of imetelstat and ruxolitinib in frontline myelofibrosis patients. Preclinical data indicated promising effects of this combination. The study will assess safety, pharmacokinetics, and clinical activity, with the first patient already dosed. Results are anticipated by late 2023. Imetelstat, a first-in-class telomerase inhibitor, shows potential in modifying disease progression in myelofibrosis, setting it apart from existing treatments.